House Bill 330 updates North Carolina’s Controlled Substances Act by expanding and clarifying the state’s lists of prohibited substances in Schedules I and II. The bill adds or revises numerous specific synthetic opioids, fentanyl analogs, nitazene derivatives, synthetic cannabinoids, substituted cathinones, and other emerging designer drugs, while also correcting and standardizing chemical names and classifications already used in the statute. It appears aimed at keeping the controlled-substances schedules current with rapidly evolving illicit drug chemistry.
The bill makes targeted amendments to G.S. 90-89 and G.S. 90-90, including adding bromazolam to Schedule IV, updating the description of 5-MeO-MiPT, refining the definition of fentanyl derivatives, and revising references to fentanyl precursor ANPP and certain anabolic steroids in G.S. 90-91. It also broadens class-based definitions for several synthetic drug families, which can make it easier for law enforcement and prosecutors to treat newly emerging analogs as controlled substances without waiting for a separate statutory update. The act becomes effective when it becomes law.
HB330 would primarily affect North Carolina’s criminal drug-control statutes by enlarging the universe of substances treated as controlled and by tightening chemical-class definitions that cover future analogs. This would impact manufacturers, distributors, possessors, and prosecutors by reducing gaps for newly synthesized opioids, cannabinoids, cathinones, benzodiazepines, and related compounds. It also updates statutory nomenclature for certain substances, which may improve consistency in enforcement and charging under Chapters 90-89, 90-90, and 90-91.
The available record suggests the bill was treated as a technical but important public-safety update, with no recorded votes or committee debate indicating opposition. Its committee substitute favorable status and movement through the House suggest general support for updating drug schedules to address fentanyl-related and other emerging synthetic drugs. Overall sentiment appears pragmatic and enforcement-oriented rather than controversial in the available materials.
No committee transcript or vote record is available, so specific objections are not documented. Based on the bill text, the most likely points of contention would be the breadth of the class-based definitions for synthetic cannabinoids and nitazenes, which can sweep in future compounds and raise concerns about overbreadth, scientific precision, or impacts on legitimate research and medical use. The bill partially addresses those concerns by excluding FDA-approved products and certain research or industrial uses, but the scope of the scheduling language remains expansive.